Not yet recruitingPhase 2NCT06990984
A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)
Studying Leigh syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Thiogenesis Therapeutics, Inc.
- Principal Investigator
- Zarazuela Zolkipli-Cunningham, MBChB, MRCPChildren's Hospital of Philadelphia
- Intervention
- TTI-0102: cysteamine-pantetheine disulfide(drug)
- Enrollment
- 18 enrolled
- Eligibility
- 5-55 years · All sexes
- Timeline
- 2025 – 2026
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06990984 on ClinicalTrials.govOther trials for Leigh syndrome
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT06843811Sirolimus for Leigh SyndromeMatthew Demczko
- RECRUITINGNCT06967831Drug Repurposing for Mitochondrial Disorders Using iPSCs Derived Neural CellsCharite University, Berlin, Germany
- RECRUITINGNANCT03137355The International Registry for Leigh SyndromeThe University of Texas Health Science Center, Houston
- RECRUITINGNCT01780168The NIH MINI Study: Metabolism, Infection, and Immunity in Inborn Errors of MetabolismNational Human Genome Research Institute (NHGRI)